Mainz Biomed B.v. Stock
Price
Target price
€6.64
€6.64
-1.480%
-0.1
-1.480%
-
05.12.24 / Stuttgart Stock Exchange
WKN: A3C6XX / Name: Mainz Biomed B.v. / Stock / ? /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Mainz Biomed B.v. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Mainz Biomed B.v.
sharewise wants to provide you with the best news and tools for Mainz Biomed B.v., so we directly link to the best financial data sources.
Financials
News
EQS-News: DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio
EQS-News: DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio
EQS-News: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
EQS-News: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
EQS-News: Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
EQS-News: Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
EQS-News: Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
EQS-News: Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
EQS-News: Mainz Biomed to Attend 2025 Maxim Growth Summit
EQS-News: Mainz Biomed to Attend 2025 Maxim Growth Summit
EQS-News: Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
EQS-News: Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
EQS-News: Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
EQS-News: Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
EQS-News: Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
EQS-News: Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
EQS-News: Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
EQS-News: Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
EQS-News: Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
EQS-News: Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
EQS-News: Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
EQS-News: Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
EQS-News: Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
EQS-News: Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
EQS-News: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
EQS-News: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test